Thomas Timbie - Nov 18, 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for Thomas Timbie
Stock symbol
TMCI
Transactions as of
Nov 18, 2022
Transactions value $
-$1,128,915
Form type
4
Date filed
11/22/2022, 08:00 PM
Previous filing
Nov 18, 2022
Next filing
Dec 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale -$852K -37.6K -2.69% $22.66 1.36M Nov 18, 2022 Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 F1, F2
transaction TMCI Common Stock Sale -$49.3K -2.1K -0.15% $23.46 1.36M Nov 18, 2022 Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 F1, F3
transaction TMCI Common Stock Sale -$4.95K -224 -0.02% $22.08 1.36M Nov 21, 2022 Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 F1, F4
transaction TMCI Common Stock Sale -$223K -10.1K -0.74% $22.11 1.35M Nov 22, 2022 Thomas E. Timbie and Pamela F. Timbie, TTEEs of the Thomas E. Timbie Rev Trust u/a dtd May 2, 2001 F1, F5
holding TMCI Common Stock 2.3K Nov 18, 2022 Direct F6
holding TMCI Common Stock 385K Nov 18, 2022 Pamela Timbie and Thomas Timbie as Trustees of the PAMELA F TIMBIE REV TRUST
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.250 to $23.230 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.250 to $23.610 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.010 to $22.180 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $22.020 to $22.640 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Represents restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on May 17, 2023 subject to Reporting Person's providing continued service to Issuer through the vesting date.